Press Releases
Corbus Pharmaceuticals Reports 2015 Third Quarter Financial Results
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation and Fast Track Status of Resunab(TM) for the Treatment of Cystic Fibrosis
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis
Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis
Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis
Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis
Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Systemic Sclerosis
Corbus Pharmaceuticals Successfully Completes Warrant Call -- Raises $11.3 mm in Total From 100% Exercise of Callable Warrants
Corbus Pharmaceuticals' Investigational Drug Resunab(TM) Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis
Corbus Pharmaceuticals Reports 2015 Second Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
Corbus Pharmaceuticals Announces Call Notice for Exercise of Warrants
Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab(TM) for the Treatment of Dermatomyositis
Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 23, 2015
Corbus Pharmaceuticals Announces Inclusion in Russell MicroCap(R) Index
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma)
Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
Corbus Pharmaceuticals Announces Presentation of Positive Data on Resunab(TM) in Pre-Clinical Models of Cystic Fibrosis at the 2015 Cystic Fibrosis Foundation Research Conference
Corbus Pharmaceuticals Receives FDA Clearance to Initiate Phase 2 Clinical Study of Resunab™ for the Treatment of Cystic Fibrosis
Corbus Pharmaceuticals Appoints Charles N. Serhan, Ph.D., to Scientific Advisory Board
Corbus Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals to Present at the Cystic Fibrosis Workshop Hosted by JMP Securities on May 8, 2015
Corbus Pharmaceuticals Receives $5 Million Development Award From Cystic Fibrosis Foundation Therapeutics to Advance Resunab™ Clinical Program
Corbus Pharmaceuticals Announces Initiation of Trading on The Nasdaq Capital Market
Corbus Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market
Corbus Pharmaceuticals Announces Presentation of Positive Data on Anti-Fibrotic Effects of Resunab™ in a Preclinical Model of Lung Fibrosis at the Experimental Biology 2015 Scientific Conference
Corbus Pharmaceuticals' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab™
Corbus Pharmaceuticals Observes Annual Rare Disease Day
Corbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015
Corbus Pharmaceuticals Reports 2014 Financial Results and Provides 2015 Business Update
Corbus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
